Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Gold/Mining/Energy : Nuvo Research Inc -- Ignore unavailable to you. Want to Upgrade?

To: Cal Gary who wrote (13647)	9/30/2004 10:41:14 AM
From: Salt'n'Peppa	Respond to of 14101

Vioxx pulled - could be great for DMX. Just wait until the lawsuits against Merck begin... Not in any more, but wish you all well with your DMX. S&P

To: Cal Gary who wrote (13647)	9/30/2004 12:33:41 PM
From: DaveAu	Respond to of 14101

Wow!!!!!! This will be huge for Celebrex and Pfizer. Could be good for DMX too if they can get anyone's attention.

To: Cal Gary who wrote (13647)	9/30/2004 2:28:38 PM
From: axial	Read Replies (1) \| Respond to of 14101

Cal, this has to be good for Pennsaid. It looks like the PP is underway, with Canaccord selling into the price appreciation. There are still legacy issues to be resolved for Pennsaid (eg., prejudice against topicals for OA, no US market as of yet, chronically underfunded marketing, more trials needed, etc) but this news couldn't have come at a better time. "Mr. Chicoine said Dimethaid's goal must be to better promote the licensing of Pennsaid and get the product to market as fast as possible in as many markets as possible." Right from the beginning, Dan Chicoine stated the necessity of getting Pennsaid to market. Not, as some chose to portray it, an effort to sidetrack Pennsaid in favour of WF10. The Vioxx news (which really applies to all Cox2 inhibitors) will finally give some weight to the longstanding (but unsubstantiated through lack of data) argument that Pennsaid is a preferable alternative, actually cost-effective in the long run. MHOs, insurers take note. Dimethaid still faces obstacles, and some big unknowns, but this is encouraging. Jim